238 |
ALK RECEPTOR TYROSINE KINASE |
ALK |
CD246 |
NBLST3 |
105590 |
427 |
ENSG00000171094 |
OTTHUMG00000152034 |
ALK tyrosine kinase receptor |
CD_antigen=CD246 |
Anaplastic lymphoma kinase |
Q9UM73 |
ALK_HUMAN |
ALK TYROSINE KINASE RECEPTOR PRECURSOR (EC 2.7.1.112) (ANAPLASTIC LYMPHOMA KINASE) (CD246 ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:Q9UM73] |
1 |
PA24719 |
T56418 |
ALK1 |
Interpro Acc | IPR001245 |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Uniprot Status | Swiss-Prot |
Human Readable Name | DRUGGABLE GENOME |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Uniprot Evidence | 1: Evidence at protein level |
Human Readable Name | KINASE |
Interpro Type | Domain |
CancerCommons Reported Gene Name | ALK, ROS |
CancerCommons Reported Gene Name | ALK |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
Gene Biotype | PROTEIN_CODING |
KINASE |
TYROSINE KINASE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | ALK tyrosine kinase receptor inhibitor |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | conflicting |
Approval Status | Preclinical |
inhibitor (inhibitory) |
Notes | |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | sensitive |
inhibitor (inhibitory) |
Reported Cancer Type | Lung |
Clinical Status | case report |
Variant Effect | gain-of-function |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Notes | Specifically targets ALK translocations |
Reported Cancer Type | Lung |
combination therapy | Saracatinib + Ceritinib |
inhibitor (inhibitory) |
Notes | |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | decreased response |
inhibitor (inhibitory) |
Approval Status | Preclinical - Cell line xenograft |
Response Type | conflicting |
Indication/Tumor Type | lung cancer |
inhibitor (inhibitory) |
Reported Cancer Type | Lung |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | resistant |
n/a |
combination therapy | Crizotinib + Onalespib |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | no benefit |
inhibitor (inhibitory) |
Mechanism of Interaction | ALK tyrosine kinase receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | ALK tyrosine kinase receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
ALK | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
ALK | Gene Symbol |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
238 | Entrez Gene Id |
ALK_HUMAN | Uniprot Id |
Q9UM73 | Uniprot Accession |
Interpro Acc | IPR001245 |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Uniprot Status | Swiss-Prot |
KINASE, DRUGGABLE GENOME |
238 | Entrez Gene ID |
CancerCommons Reported Gene Name | ALK, ROS |
CancerCommons Reported Gene Name | ALK |
ALK | Display Id |
ALK TYROSINE KINASE RECEPTOR PRECURSOR (EC 2.7.1.112) (ANAPLASTIC LYMPHOMA KINASE) (CD246 ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:Q9UM73] | Description |
ENSG00000171094 | Ensembl Gene Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
238 | CKB Entrez Id |
ALK | CKB Gene Synonym |
CD246 | CKB Gene Synonym |
PA24719 | PharmGKB ID |
238 | Entrez Gene ID |
1 | CIViC Gene ID |
DRUG RESISTANCE, CLINICALLY ACTIONABLE |
ALK | Gene Symbol |
ENSG00000171094 | Gene Symbol |
ALK | Ensembl Id |
DRUGGABLE GENOME |
238 | Entrez Gene Id |
ALK | MyCancerGenome Gene Symbol |
ALK | MyCancerGenome Reported Gene Name |
ALK | GENE_SYMBOL |
ALK tyrosine kinase receptor | UNIPROT |
Anaplastic lymphoma kinase | UNIPROT |
238 | OncoKB Entrez Id |
NBLST3 | OncoKB Gene Synonym |
CD246 | OncoKB Gene Synonym |
ALK | Gene Symbol |
CLINICALLY ACTIONABLE |
238 | Gene ID |
CD246 | dGene Synonym |
NBLST3 | dGene Synonym |
KINASE, TYROSINE KINASE |
ALK | TTD Gene Abbreviation |
T56418 | TTD Target ID |
ALK tyrosine kinase receptor | Gene Name |
Q9UM73 | UniProt ID |
KINASE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
TYROSINE KINASE |
CLINICALLY ACTIONABLE |
DRUG RESISTANCE |